Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

SkyRx vs Spry

SkyRx
Graded #353

Higher grade

vs+2.1000000000000014
Spry
Graded #409

Lower grade

The verdict

SkyRx takes it — 58.9/100 to 56.8/100.

SkyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. SkyRx (sky-rx.co) is a US telehealth weight-loss program offering compounded semaglutide as an injection or oral drops, with compounded tirzepatide listed as coming soon.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSkyRx +2
56
54
Dose & formulationSkyRx +7
71
64
Clinical oversightSkyRx +13
68
55
Labs & monitoringEven
52
52
FulfillmentSkyRx +3
64
61
Contract termsSpry +35
20
55
SkyRx · left barSpry · right bar

The numbers

MetricSkyRxSpry
WeighScore58.9/10056.8/100
GradeCC
Scorecard rank#353#409
Semaglutide$199/mo (all doses, 12-month plan, compounded)$199/mo (starting dose, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
SkyRx

Graded #353 · C

Strengths

  • All-inclusive 199 dollars per month covers medication, supplies, doctor visit and shipping
  • Offers both injectable and oral semaglutide, dispensed by FDA-registered 503B pharmacies
  • Same-day shipping for orders before 2pm ET in temperature-controlled packaging

Where it loses points

  • 199 dollars pricing requires a 12-month subscription paid upfront
  • Tirzepatide only listed as coming soon
  • GLP-1s not yet available in all 50 states; specific states not listed
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard